prikaz prve stranice dokumenta Real-life experience with remdesivir for treatment of hospitalized coronavirus disease 2019 patients: matched case-control study from a large tertiary hospital registry
  Download
PDF 913.81 KB
Scientific paper - Original scientific paper
Real-life experience with remdesivir for treatment of hospitalized coronavirus disease 2019 patients: matched case-control study from a large tertiary hospital registry
Croatian Medical Journal, 63 (2022), 6; 536-543. https://doi.org/10.3325/cmj.2022.63.536
Lucijanić, Marko; Bušić, Nikolina; Bistrović, Petra; Papić, Ivan; Zelenika Margeta, Marina; Babić, Paško; Barčan, Mihaela; Pasarić, Antica; Mustapić, Mirna; Piskač Živković, Nevenka; Ortner Hadžiabdić, Maja; Lucijanić, Tomo; Lukšić, Ivica; Baršić, Bruno

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Lucijanić, M., Bušić, N., Bistrović, P., Papić, I., Zelenika Margeta, M., Babić, P. ... Baršić, B. (2022). Real-life experience with remdesivir for treatment of hospitalized coronavirus disease 2019 patients: matched case-control study from a large tertiary hospital registry. Croatian Medical Journal, 63. (6), 536-543. doi: 10.3325/cmj.2022.63.536

Lucijanić, Marko, et al. "Real-life experience with remdesivir for treatment of hospitalized coronavirus disease 2019 patients: matched case-control study from a large tertiary hospital registry." Croatian Medical Journal, vol. 63, no. 6, 2022, pp. 536-543. https://doi.org/10.3325/cmj.2022.63.536

Lucijanić, Marko, Nikolina Bušić, Petra Bistrović, Ivan Papić, Marina Zelenika Margeta, Paško Babić, Mihaela Barčan, et al. "Real-life experience with remdesivir for treatment of hospitalized coronavirus disease 2019 patients: matched case-control study from a large tertiary hospital registry." Croatian Medical Journal 63, no. 6 (2022): 536-543. https://doi.org/10.3325/cmj.2022.63.536

Lucijanić, M., et al. (2022) 'Real-life experience with remdesivir for treatment of hospitalized coronavirus disease 2019 patients: matched case-control study from a large tertiary hospital registry', Croatian Medical Journal, 63(6), pp. 536-543. doi: 10.3325/cmj.2022.63.536

Lucijanić M, Bušić N, Bistrović P, Papić I, Zelenika Margeta M, Babić P, and sur.. Real-life experience with remdesivir for treatment of hospitalized coronavirus disease 2019 patients: matched case-control study from a large tertiary hospital registry. Croatian Medical Journal [Internet]. 2022 December 31 [cited 2024 December 26];63(6):536-543. doi: 10.3325/cmj.2022.63.536

M. Lucijanić, et al., "Real-life experience with remdesivir for treatment of hospitalized coronavirus disease 2019 patients: matched case-control study from a large tertiary hospital registry", Croatian Medical Journal, vol. 63, no. 6, pp. 536-543, December 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:523196. [Accessed: 26 December 2024]

Metadata
Title (english)Real-life experience with remdesivir for treatment of hospitalized coronavirus disease 2019 patients: matched case-control study from a large tertiary hospital registry
AuthorMarko Lucijanić
AuthorNikolina Bušić
AuthorPetra Bistrović
AuthorIvan Papić
AuthorMarina Zelenika Margeta
AuthorPaško Babić
AuthorMihaela Barčan
AuthorAntica Pasarić
AuthorMirna Mustapić
AuthorNevenka Piskač Živković
AuthorMaja Ortner Hadžiabdić
AuthorTomo Lucijanić
AuthorIvica Lukšić
AuthorBruno Baršić
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Maxillofacial Surgery and Dentistry)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Surgery
Abstract (english)
Aim: To evaluate the association of remdesivir use and the survival of hospitalized patients with coronavirus disease 2019 (COVID-19). ----- Methods: We retrospectively reviewed the medical records of 5959 COVID-19 patients admitted to our tertiary-level hospital from March 2020 to June 2021. A total of 876 remdesivir-treated patients were matched with 876 control patients in terms of age, sex, Charlson comorbidity index (CCI), WHO-defined COVID-19 severity on admission, and oxygen requirement at the time of remdesivir use. ----- Results: Among 1752 COVID-19 patients (median age 66 years, 61.8% men), 1405 (80.2%) had severe and 311 (17.8%) had critically severe COVID-19 on admission. Remdesivir was given at a median of one day after hospital admission and at a median of eight days from the onset of symptoms. Overall, 645 (73.6%) patients received remdesivir before high-flow oxygen therapy (HFOT) or mechanical ventilation (MV), 198 (22.6%) after HFOT institution, and 83 (9.5%) after MV institution. Remdesivir use was associated with improved survival in the entire cohort (hazard ratio 0.79, P=0.006). Survival benefit was evident among patients receiving remdesivir during low-flow oxygen requirement (hazard ratio 0.61, P<0.001) but not among patients who received it after starting HFOT (P=0.499) or MV (P=0.380). ----- Conclusion: Remdesivir, if given during low-flow oxygen therapy, might be associated with survival benefit in hospitalized COVID-19 patients.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleCroatian Medical Journal
Numberingvol. 63, no. 6, pp. 536-543
p-ISSN0353-9504
e-ISSN1332-8166
DOIhttps://doi.org/10.3325/cmj.2022.63.536
URN:NBNurn:nbn:hr:105:523196
Publication2022-12-31
Document URLhttp://www.cmj.hr/2022/63/6/36597565.htm
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) icon
Created on2023-01-16 12:48:19